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Involvement of the vena cava by retroperitoneal
malignancy is generally indicative of advanced dis-
ease and is often considered a contraindication to
attempted resection. The ability of non-surgical
therapy to cure or palliate these tumors is variable
and dependent on the tumor type, but generally in
the absence of surgical resection, patient survival is
limited.1 Tumors originating in the kidney, adrenal
gland, soft tissues of the retroperitoneum as well as
the liver may invade the inferior vena cava and have
a dismal prognosis regardless of tumor type if resec-
tion is not possible.1–3
Caval involvement has traditionally been suspect-
ed by the presenting symptoms of lower extremity
swelling and venous engorgement.1, 4 The wide-
spread use of preoperative computerized tomogra-
phy scans has demonstrated that many asymptomatic
patients have involvement of the vena cava by tumor,
and venograms in these patients have demonstrated
extensive venous collaterals that reconstitute the
vena cava above the level of obstruction by tumor.5
Although these patients may not manifest symptoms
of their caval obstruction preoperatively because of
adequate collateral flow, resection of the tumor
often disrupts the retroperitoneal collaterals. If the
removal of the tumor includes caval resection and
ligation, then venous drainage through both the col-
laterals as well as the cava is lost. Thus patients who
were asymptomatic before resection have been
reported to manifest symptoms of venous obstruc-
tion in the lower extremities postoperatively.1
Recent reports have centered on the use of vari-
ous techniques to aid in the achievement of com-
plete tumor resection.2, 5 These include preoperative
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chemotherapy, either alone or in conjunction with
radiotherapy, to attempt shrinkage of tumors.
Postoperative radiation therapy can theoretically aid
in local control of residual microscopic disease,
although many soft-tissue sarcomas are relatively
radioresistant. Caval resection and reconstruction
techniques, including patch reconstruction with
either prosthetic material or autogenous vein as well
as replacement of entire segments of the cava with
prosthetic tube grafts, have been described as allow-
ing successful complete extirpation of otherwise
unresectable tumors.2, 3
However, the examination of patients after mod-
ern resection techniques of the inferior vena cava has
been limited. Aside from individual case reports, the
two large clinical series reported to date2, 3 both
involve inferior vena caval resection and replacement
as an adjunct to major liver resection in the majority
(75%) of patients and have outcome data that is lim-
ited by short follow-up (mean follow-up periods of
8.8 months2 and 15 months3). Experience with this
type of operation at an individual institution remains
very limited, with the two largest series having only
eight and four patients, respectively.2, 3
The purpose of this study was to determine the
outcomes of our experience with prosthetic replace-
ment of the vena cava for retroperitoneal malignan-
cies. Our experience reflects that of a tertiary refer-
ral center for complex oncology patients in a num-
ber of surgical disciplines, and thus a variety of
tumors were encountered, similar to that of previous
reports of regional referral centers.2 The focus was
on the long-term outcome of replacement of the
inferior vena cava with a prosthetic tube graft, unlike
other studies that include reconstructions of both
the superior and inferior vena cava with a variety of
materials.2–4 Consequently, we specifically excluded
patients with similar tumors who underwent caval
resections involving reconstruction with either a
prosthetic patch or autologous materials. 
METHODS
A review of all available medical records at
UCLA Medical Center identified 19 patients who
underwent vena caval surgery as a part of an onco-
logic resection. Of these, nine had either a prosthet-
ic patch repair of the cava, an autologous patch
reconstruction, or simple ligation. These patients
were consequently excluded from this review, leav-
ing 10 patients who underwent replacement of a
segment of the inferior vena cava with a prosthetic
tube graft. These patients were treated in a four-year
period (1993-1997). There were eight females and
two males, with a mean age of 54.1 years and an age
range of 36 to 72 years. 
Medical records were reviewed and pertinent data
regarding presenting symptoms, diagnostic evalua-
tion, surgery, and postoperative course were extract-
ed. Follow-up was conducted by outpatient examina-
tion or telephone, and symptoms were classified
according to the updated reporting standards of the
Society for Vascular Surgery (SVS) and the North
American Chapter of the International Society for
Cardiovascular Surgery (ISCVS).6 Functional status
of the patients was determined according to the
Performance Status classification of the Eastern
Cooperative Oncology Group (ECOG).7 Repeat
duplex studies were attempted in every patient at the
time of this review; however, the wide geographic
distribution of these referral patients made access to
these follow-up studies difficult for most patients.
RESULTS
Preoperative evaluation 
All patients underwent preoperative CT scan-
ning of the abdomen and pelvis with intravenous
and oral contrast (Fig. 1A). Venograms were per-
formed in three of 10 patients by referring physi-
cians (Fig. 1B), but were not routinely done preop-
eratively. Two of these demonstrated caval occlu-
sion, and one showed significant narrowing. Tumor
histology included leiomyosarcoma arising from the
IVC or retroperitoneum in seven patients, teratoma
(one), renal cell carcinoma (one), and adrenal lym-
phoma (one). Four patients (three with leiomyosar-
coma, one with teratoma) were treated with preop-
erative chemotherapy; none received preoperative
radiation therapy. No patient had symptoms of
venous obstruction. 
Surgery
All patients were explored through an anterior
abdominal incision. Mean estimated blood loss was
1789 ml (range 500–4000 ml), and an average of 2
units of red blood cells (range 0–7 units) were trans-
fused intraoperatively. Ringed PTFE grafts were
used in all patients, and diameters ranged from 12
mm for an iliac vein to 16 mm for an IVC graft. The
most common (7/10, 70%) graft size was 14 mm.
Seven patients had replacement of the infrarenal
IVC (Fig. 1C), two of their suprarenal IVC, and one
had reconstruction of the IVC bifurcation. No
patient underwent replacement of the retrohepatic
IVC, and hepatic vascular exclusion was not
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Fig. 1. A, Preoperative computerized tomography, showing large retroperitoneal tumor with
vena cava involvement. B, Preoperative venogram, showing tumor invasion of the perirenal
vena cava. Continued
Fig. 1. Cont’d C, Resection required removal of the right kidney in conjunction with the
suprarenal and infrarenal vena cava, and prosthetic replacement and reimplantation of the left
renal vein into graft. Note preservation of rings in the area of implantation of the left renal
vein. Graft chosen to be smaller than proximal and distal remaining cava. D, Follow-up duplex
scan on patient with inferior vena cava replacement, showing patency of the graft.
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required in any patient. An adjunctive groin arteri-
ovenous fistula2 to increase flow through the graft
was not used in any patient. Intra-operative heparin
was used in only one patient, who had both renal
veins clamped and then sequentially reimplanted
into the prosthetic graft. 
There were no perioperative deaths, and the
mean duration of hospital stay was 8.1 days. There
were no re-operations. Negative tumor margins
were obtained in all patients. One postoperative
complication occurred, consisting of prolonged ileus
that resolved without additional intervention.
Pulsatile compression boots and graduated pressure
stockings were used in all patients. Anticoagulation
was not used postoperatively. There were no post-
operative episodes consistent with venous obstruc-
tion, and CT scans or duplex studies obtained in six
of the 10 patients before discharge demonstrated
patency of the IVC graft in all six. 
Follow-up 
The mean duration of follow-up was 19 months.
There were eight survivors and two deaths because
of recurrent disease. The average time to death was
14 months, and the average time of survival is 21
months. This average survival represents a dispro-
portionate number of operations performed within
the past year (4/7); the other three survivors have all
lived longer than three years. 
Patency of the IVC grafts was assessed by either
imaging studies or clinical follow-up. The patency
of five of the eight grafts has been confirmed by
either duplex scan (Fig. 1D) or contrast-enhanced
CT scan (mean follow-up 16 months). A graft was
defined as being clinically functional if there were
no signs or symptoms of venous obstruction, rec-
ognizing that the latter may occur in spite of an
occluded graft. The basis for this definition includes
the finding that ligation of an occluded IVC with-
out reconstruction results in clinical venous
obstruction,1 because of concomitant ligation or
resection of collateral pathways. This is further sup-
ported by the immediate onset of venous obstruc-
tive symptoms in the single patient with late post-
operative graft occlusion. This patient had a graft
known to be patent by duplex at the time of dis-
charge that occluded 10 months later during a pro-
longed period of immobilization and hypovolemia
secondary to chemotherapy-induced neutropenic
sepsis. The patient is currently on oral anticoagula-
tion. Both patients who died had clinically func-
tional grafts at the time of death. Autopsies were
not performed. The mean follow-up in the three
remaining grafts defined as clinically functional was
21 months. Overall, 90% (9/10) of grafts were
patent or clinically functional at follow-up (Fig. 2),
and 88% (7/8) of surviving patients were free of
venous symptoms. 
The functional status of the surviving patients is
good, with six able to undertake strenuous activity
without limitations (ECOG Performance Status 0).
The two remaining patients live independently and
ambulate with some assistance (ECOG Performance
Status 2). Only one patient, with graft occlusion sec-
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Fig. 2. Graph illustrating status of IVC grafts at follow-up.
ondary to neutropenic sepsis, is taking long-term oral
anticoagulation. Using the SVS/ISCVS reporting
standards for venous disease6, this patient has Class 3
venous changes (edema without skin changes);
another patient has Class 2 disease (varicose veins),
and the other six surviving patients have Class 0
(none) disease. 
DISCUSSION
The findings in our study of prosthetic replace-
ment of the IVC for the treatment of malignancy
support the view that caval replacement can be done
safely with good long-term functional results.2 This
report of 10 patients represents the largest series in
the literature to date of patients with prosthetic
replacement of the IVC. The survival after aggres-
sive resection of these tumors is measured in years,
and our study confirms this with double the follow-
up period (19 vs. nine months) of the other long-
term series in the literature.2 The ability to safely
accomplish caval resection without perioperative
death and the excellent functional results in terms of
patient activity are also noted in our series.
However, there are several significant differences
between our study and the two series previously
reported.2, 3 In the majority of patients (75%)
undergoing graft replacement of the cava in both
prior studies, concurrent major liver resection was
performed. In contrast, none of the patients in this
study had concurrent major liver resection because
the tumors primarily originated from the cava itself
or the adjacent kidney or adrenal. In the prior-
reported series the most common tumors were pri-
mary or metastatic tumors arising in the liver, and
consequently 75% of those cases involved resection
and replacement of the retrohepatic IVC. Although
our patients had tumors originating from a variety of
retroperitoneal organs (Table 1), they all had resec-
tion and replacement of various segments of the
infrahepatic IVC. Thus our experience is more
reflective of malignancy arising in or around the
cava, rather than a caval resection as an adjunctive
maneuver to aid in an extended hepatectomy. Not
surprisingly, the operative incision and blood loss are
also very different in our series from other reports in
which IVC replacement accompanied major hepatic
resection.2 When hepatic resection was involved, a
thoracoabdominal incision was routinely used, and
the transfusion requirement was more than twice
that of our experience.2 This difference is also illus-
trated by the lack of use of hepatic vascular exclusion
in our series, as compared with the two prior series,
in which 77% of patients required this maneuver and
44% required veno-venous pump bypass.2, 3
The use of ring-reinforced PTFE is common for
replacement of the IVC.2, 3 The ring-reinforcement
in theory resists respiratory compression better, and
thus prevents graft collapse that may be a factor in
promotion of thrombosis. Experimental studies con-
firm the ability of ring-reinforcement to prevent
hemodynamic changes associated with graft defor-
mation.8 A comparative study with non-ringed
grafts has not been done and is not feasible given the
small numbers of patients in even the largest reports
with this technique. We generally favor placement of
a graft smaller than the surrounding native cava, as
this promotes a higher blood velocity through the
graft and thus may minimize blood-prosthetic inter-
actions that promote thrombus formation. We did
not use groin arteriovenous fistula to increase IVC
blood flow as others have reported.2
Routine anticoagulation was not used either
intraoperatively or postoperatively, and the good
long-term patencies achieved using this strategy in
our series make us question the suggestion that life-
long oral anticoagulation is required with prosthetic
replacement of the IVC.2 The one episode of graft
thrombosis in our experience occurred in a patient
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Table I. Patient data. 
Follow-up
Patient number Age/Gender Tumor type Caval segment (months) Status/Symptoms Patency assessment
1 56/F Leiomyosarcoma Infrarenal 10 Lower extremity edema Duplex (occluded)
2 58/M Leiomyosarcoma Perirenal 7 No symptoms Clinically functional
3 69/F Renal cell Suprarenal 8 No symptoms CT scan
4 72/F Leiomyosarcoma Entire IVC 18 Died 18 months Clinically functional
5 41/F Leiomyosarcoma Infrarenal 9 Died 9 months Clinically functional
6 43/F Leiomyosarcoma Infrarenal 48 No symptoms Clinically functional
7 55/F Adrenal lymphoma Infrarenal 32 No symptoms CT scan
8 66/F Leiomyosarcoma Infrarenal 32 No symptoms Duplex
9 45/M Teratoma Iliac + infrarenal 7 No symptoms Clinically functional
10 45/F Leiomyosarcoma Infrarenal 19 No symptoms CT scan
who subsequently became critically ill and hypov-
olemic 10 months after caval replacement. This
experience, although quite anecdotal, suggests that
short-term anticoagulation should be instituted
when a known risk factor for venous thrombosis
(e.g., immobilization, dehydration, or subsequent
major surgery) develops in a patient with a prior
IVC prosthetic graft. 
Despite the majority of patients (7/10, 70%) in
our series who had a leiomyosarcoma of the IVC, no
patient had symptoms or signs of venous obstruc-
tion. This is consistent with other large reviews of
IVC leiomyosarcoma, which note that only 20% to
30% of patients have venous symptoms, presumably
because of the development of large retroperitoneal
collaterals.1, 5, 9 The argument has been made that
replacement of the IVC with prosthetic material is
unnecessary in asymptomatic patients and even in
patients with venous symptoms.1, 9
Long-term survival in patients with leiomyosar-
coma of the IVC is dependent on radical resection,
and neither chemotherapy nor radiation therapy
have increased long-term survival.1, 5 Survival after
complete resection of leiomyosarcoma of the IVC is
significantly greater than sarcomas of either the
aorta or pulmonary artery.10 The ability of caval
resection to contribute to successful radical resection
is illustrated by the finding that negative tumor mar-
gins were achieved in every patient in our series. 
Our indications for replacement of asymptomatic
occluded cava include any situation in which the
retroperitoneal dissection or resection has removed
the pre-existing collaterals. This is often the case in
oncologic resection. We would not recommend
caval replacement if there is hemodynamic instabili-
ty or bilateral iliac occlusion that would make re-
establishment of venous continuity within the
abdomen impossible or hazardous. Our series
includes one patient who had an iliac to suprarenal
IVC graft for a pelvic teratoma (Table 1, Patient #9). 
The limitations of the present study include the
relatively short mean follow-up period and the lack
of follow-up duplex studies in all patients. The use of
CT scan for follow-up gives an overall image of con-
trast flow through the graft, but may miss smaller
areas of thrombus deposition that theoretically
could either embolize or predispose to graft throm-
bosis. An average follow-up of 19 months does not
mean that late graft occlusion will not subsequently
occur, and there is the small possibility that a patient
may have an asymptomatic graft occlusion, as has
been described only once before in the literature.11
The one patient in our study who had both clinical
and duplex evidence of sudden graft occlusion is the
only patient described with clinical evidence of graft
occlusion. Thus there appears to be good correlation
between symptoms and graft occlusion after surgical
resection of the collaterals, in contrast to the preop-
erative state, during which gradual occlusion is often
tolerated because of development of retroperitoneal
collaterals.
Radical resection of a retroperitoneal tumor
often disrupts collateral venous channels, and the
use of simple ligation of the IVC is associated with
postoperative venous symptoms that have required
long-term anticoagulation.1 In contrast, our results
demonstrate that prosthetic IVC replacement can be
safely accomplished without intraoperative or post-
operative anticoagulation and that function of both
grafts and patients is good. 
REFERENCES
1. Mingoli A, Feldhaus RJ, Cavallaro A, Stipa S. Leiomyosarcoma
of the inferior vena cava: Analysis and search of the world liter-
ature and report of three new cases. J Vasc Surg 1991;
14:688–99.
2. Bower TC, Nagorney DM, Toomey BJ, Gloviczki P, Pairolero
PC, Hallett JW, et al. Vena cava replacement for malignant
disease: Is there a role? Ann Vasc Surg 1993;7:51–62.
3. Huguet C, Ferri M, Gavelli A. Resection of the suprarenal
inferior vena cava. The role of prosthetic replacement. Arch
Surg 1995;130:793–7.
4. Kieffer E, Bahnini A, and Koskas F. Nonthrombotic disease of
the inferior vena cava: Surgical management of 24 patients. In:
Bergan JJ, Yao JST, editors. Venous Disorders. Philadelphia:
W.B. Saunders; 1991. p. 501–16.
5. Dzsinich C, Gloviczki P, van Heerden JA, Nagorney DM,
Pairolero PC, Johnson CM, et al. Primary venous leiomyosar-
coma: A rare but lethal disease. J Vasc Surg 1992;15:595–603.
6. Porter JM, Moneta GL. An International Consensus
Committee on Chronic Venous Disease. Reporting standards
in venous disease: An update. J Vasc Surg 1988;21:635–45.
7. Beahrs OH, Henson DE, Hutter RVP Myers MH. General
rules for staging cancer. In: American Joint Committee on
Cancer. Manual for Staging of Cancer. Philadelphia: JB
Lippincott; 1988. p. 9.
8. Karacagil S, Bowald S, Almgren B, Bergqvist D. Influence of
twist on vein and PTFE graft hemodynamics: An ex vivo
experimental study. Panminerva Medica 1997;39:95–9.
9. Bruyninckx CMA, Derksen OS. Leiomyosarcoma of the vena
cava. Case report and review of the literature. J Vasc Surg
1986;3:652–6.
10. Burke AP, Virmani R. Sarcomas of the great vessels. A clini-
copathologic study. Cancer 1993;71:1761–73.
11. Gloviczki P, Pairolero PC, Toomey BJ, Bower TC, Rooke
TW, Stanson AW, et al. Reconstruction of large veins for non-
malignant venous occlusive disease. J Vasc Surg 1992;
16:750–61.
Submitted Oct. 7, 1997; accepted Feb. 27; 1998.
JOURNAL OF VASCULAR SURGERY
Volume 28, Number 1 Sarkar et al. 81
Dr. Robert C. Lim, Jr. (San Francisco, Calif.). The
goal of cancer surgery is to resect for cure, which requires
resecting all visible and microscopic tumors. For tumors
that invade the inferior vena cava (IVC), the principle is no
different. This paper restates that the IVC can be resected
and replaced with a graft. I commend the authors for
bringing this to our attention. In cancer of the IVC, the
tumor either arises from the IVC, as in leiomyosarcoma,
extends into the IVC, as in renal cell carcinoma, or invades
into the IVC, as in adrenal cell carcinoma.
Most of the time, IVC obstruction by tumor is slow,
and collateral flow develops, which might make en bloc
resection possible without canal reconstruction. The mor-
bidity rates from venous hypertension in these cases are
minimal. This paper draws our attention to the small per-
centage of cases when venous hypertension is unaccept-
able and a graft is necessary.
Again, the goal of resection of the cancer is en bloc
resection; reconstruction is next. Simple ligation of the
IVC can be done in the infrarenal segment. If involvement
is extensive, reconstruction with a graft may be necessary
as described by the authors. I wish to submit a third
method, which is primary end-to-end anastomosis. To
bridge a small gap, ligation and division of a number of
lumbar veins above and below the gap plus ligation and
division of the hypogastric veins to mobilize the iliac veins,
as in renal transplantation, will allow the entire venous sys-
tem to give you a segment of vein for a tension-free anas-
tomosis.
This leads to my first question to the authors. Can you
give information on the length of the IVC involved in the
resection leading to the use of a graft?
In the manuscript, the authors used the term “clini-
cally patent.” What does this mean? Does this mean no leg
edema or swelling? Vascular surgeons in the late 1960s
and early 1970s performed a large number of emergency
venous thrombectomies for acute ileofemoral throm-
bophlebitis. The immediate results were dramatic; the
swelling decreased and the pain disappeared. All patients
were “clinically improved.” Dr. Karp and the late Dr.
Wylie studied a group of these patients and reported a
high thrombosis rate in spite of good clinical outcome.
Therefore, I would be careful in reporting patency with-
out hard data.
The mean survival of patients with IVC cancer has
been reported at about 40 months. The prognosis is poor
in these patients. In the group of surviving patients pre-
sented, half were in the last year and three were in the last
3 years of the 4-year study. I do not believe that we have
had a good long-term result yet. The long-term function
of graft and patient is not known clearly at this time. I did
not see any follow-up abdominal computed tomography
data on these patients in the manuscript. Would the
authors share this if they have it?
In closing, I can agree with the fist part of the authors’
conclusion “that resection of the IVC with prosthetic
reconstruction safely allows for complete tumor resec-
tion.” However, I am not convinced on their statement
that “it provides durable relief from symptoms of venous
obstruction.” The sequel of chronic venous hypertension
often takes years to develop.
Dr. William J. Quinones-Baldrich. Thank you, Dr.
Lim, for your comments and the review of our manuscript.
We specifically eliminated from inclusion in this study
patients who underwent primary repair of the vena cava
where either a primary end-to-end anastomosis or some
type of patch reconstruction, either autogenous or pros-
thetic, was used to close the gap created by the resection.
So, these are all cases where the entire vena cava was
replaced with a prosthetic graft.
Your first question asked how much length of vena
cava above and below the graft is necessary for a complete
resection. This was done by gross examination and then
confirmed with frozen sections of the margins of the cava.
In these cases, this translates to about 2 cm or more of
normal vena cava above and below the tumor. In all of
these patients, the margins were negative.
You also asked what clinically patent meant. These
were patients in whom no symptoms of venous insuffi-
ciency were seen during the follow-up period; however,
we did not have any radiologic confirmation of patency.
These patients were three of the eight survivors. Five of
the eight grafts were found to be patent, either by duplex
scan or by computed tomography scan with contrast. So,
at least we have radiologic confirmation of graft patency in
five of the eight survivors.
I believe that you are correct in stating that we do not
have long-term follow-up in these patients. However, if you
look at the oncologic literature on inferior vena cava tumors,
the average survival rate is about 16 months. We are now at
an average of 21 months survival in patients who have
undergone this procedure. We feel confident that the thor-
oughness of the resection is contributing to survival. We
continue to be enthusiastic about this approach and now
offer it to patients who have involvement of the vena cava
where complete resection requires removal of that structure.
Dr. Robert B. Rutherford (Silverthorn, Colo.). Do
you have a control group of patients in whom the tumor
was resected and the cava was also resected but not recon-
structed for comparison? Also, what are your criteria for
deciding that a particular malignant involvement of the
cava requires reconstruction? Do you measure pressures or
just signs of venous congestion? Is it a decision that you
before or during operation?
Dr. Quinones-Baldrich. These cases are referred to
the oncology service. In the past, before 1990, these
patients were approached by resection and ligation of the
cava. There was concern not only with the relatively poor
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survival rate but also with development of venous symp-
toms, particularly in the first few months after surgery.
These symptoms tend to resolve with time as these
patients develop new collaterals. However, the periopera-
tive period was complicated somewhat by lower-extremity
edema. It is on the basis of that experience that we start-
ed approaching these patients with complete resection and
replacement of the vena cava.
We do not have a contemporary or parallel experience
with the two approaches. What we have to compare are the
results of our prior approach and those presented today.
Mean survival has increased by about 5 months. We think
this is probably a combination of better resection and avoid-
ance of perioperative edema that was seen after resection
and caval ligation.
Dr. Carlos Donayre (Torrance, Calif.). I commend
you and your group on a nice presentation. I have a
question about the five patients who had radiographic
follow-up. Could you comment about whether any of
them had the renal veins reattached to the polytetraflu-
oroethylene graft? If so, did they remain patent? I am
not as concerned about patency in the large diameter
vena cava as in the smaller renal veins.
Dr. Quinones-Baldrich. One of the patients who
had the renal vein attached to the graft has been exam-
ined by computed tomography scan. The entire recon-
struction was found to be patent. The patient, who had
both renal veins attached to the graft, has not been
studied radiologically, but his creatinine has remained
normal.
JOURNAL OF VASCULAR SURGERY
Volume 28, Number 1 Sarkar et al. 83
